

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT JACOBIO PRESENTS CLINICAL RESULTS OF GLECIRASIB IN COLORECTAL CANCER

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the Company has announced clinical results of in-house novel KRAS G12C inhibitor Glecirasib (JAB-21822) monotherapy and in combination with cetuximab to treat KRAS G12C mutant advanced colorectal cancer(CRC) in Second JCA-AACR Precision Cancer Medicine International Conference.

In the monotherapy study, overall response rate (ORR) is 33.3% (11/33), disease control rate (DCR) is 90.9% (30/33), mPFS (median progression-free survival) is 6.9 months.

In a clinical trial of Glecirasib with cetuximab, ORR is 62.8% (27/43), DCR is 93% (40/43), mPFS has not reached before the May 23, 2023 data cutoff date.

In terms of safety, the majority of treatment-related adverse events (TRAEs) in monotherapies and combinations are grades 1-2.

Colorectal cancer is the second most common cancer in China, with about 550,000 new cases per year, of which about 3% of colorectal cancer patients have KRAS G12C mutation. Patients with KRAS G12C mutation are insensitive to existing standard chemotherapies and targeted therapies, have rapid disease progression, short survival, and they have high unmet clinical treatment needs. Glecirasib has the potential to bring effective and less toxic treatment option for patients.

About Glecirasib

Glecirasib is Jacobio’s novel KRAS G12C inhibitor independently developed by the Company. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors harbouring KRAS G12C mutation, including a pivotal clinical trial to treat non-small cell lung cancer (NSCLC) in China, a monotherapy study for STK11 co-mutated NSCLC in the front-line setting; combination therapy trials with SHP2 inhibitor JAB-3312, anti-PD-1 monoclonal antibody and Cetuximab.

About Jacobio

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

About JCA-AACR Conference

JCA-AACR conference is co-organized by Japanese Cancer Association and American Association of Cancer Research (AACR). Please visit the official website for more information: <https://www.aacr.org/meeting/2nd-jca-aacr-precision-cancer-medicine-international-conference/>

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that Glecirasib (JAB-21822) will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.jacobiopharma.com for more information.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, June 29, 2023

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.